Segment Information (Tables)
6 Months Ended
Apr. 30, 2011
Segment Information [Abstract]  
Reconciliation of reportable segment results to total enterprise from operations before taxes
The following table reconciles reportable segment results to Agilent's total enterprise results from operations before taxes:
 
 
 
Three Months Ended
April 30,
  
Six Months Ended
April 30,
 
 
 
2011
  
2010
  
2011
  
2010
 
 
 
(in millions)
 
Total reportable segments' income from operations
 $324  $205  $593  $385 
Restructuring related costs and asset impairments
  (3)  (16)  (5)  (64)
Transformational initiatives
  (11)  (6)  (22)  (15)
Interest income
  3   3   7   6 
Interest expense
  (20)  (22)  (43)  (45)
Other income (expense), net
  11   4   17   13 
Acquisition and integration costs
  (13)  (10)  (28)  (27)
Varian acquisition related fair value adjustments
  (3)  -   (7)  - 
Amortization of Intangibles and Other
  (28)  (19)  (54)  (31)
Income before taxes, as reported
 $260  $139  $458  $222 

Segment profitability and segment assets
The following tables reflect the results of our reportable segments under our management reporting system. These results are not necessarily in conformity with U.S. GAAP. The performance of each segment is measured based on several metrics, including adjusted income from operations. These results are used, in part, by the chief operating decision maker in evaluating the performance of, and in allocating resources to, each of the segments.
 
The profitability of each of the segments is measured after excluding restructuring and asset impairment charges, investment gains and losses, interest income, interest expense, acquisition and integration costs, non-cash amortization and impairment of other intangibles and other items as noted in the reconciliations below.
 
 
 
Life Sciences
  
Chemical
Analysis
  
Electronic
Measurement
  
Total
 
 
 
(in millions)
 
Three months ended April 30, 2011:
 
 
  
 
  
 
  
 
 
Total segment revenue
 $464  $381  $834  $1,679 
Varian acquisition deferred revenue fair value adjustment
 $(1) $(1) $-  $(2)
Total net revenue
 $463  $380  $834  $1,677 
Segment income from operations
 $61  $72  $191  $324 
Three months ended April 30, 2010:
                
Total net revenue
 $334  $238  $699  $1,271 
Segment income from operations
 $48  $57  $100  $205 
 
 
 
Life Sciences
  
Chemical
Analysis
  
Electronic
Measurement
  
Total
 
 
 
(in millions)
 
Six months ended April 30, 2011:
 
 
  
 
  
 
  
 
 
Total segment revenue
 $868  $730  $1,605  $3,203 
Varian acquisition deferred revenue fair value adjustment
 $(4) $(3) $-  $(7)
Total net revenue
 $864  $727  $1,605  $3,196 
Segment income from operations
 $109  $137  $347  $593 
Six months ended April 30, 2010:
                
Total net revenue
 $674  $482  $1,328  $2,484 
Segment income from operations
 $103  $124  $158  $385 
 
The following table reflects segment assets under our management reporting system. Segment assets include allocations of corporate assets, including deferred tax assets, goodwill, other intangibles and other assets. Unallocated assets primarily consist of cash, cash equivalents, accumulated amortization of other intangibles and the valuation allowance relating to deferred tax assets.
 
 
 
Life Sciences
  
Chemical
Analysis
  
Electronic
Measurement
  
Total
 
 
 
(in millions)
 
Assets:
 
 
  
 
  
 
  
 
 
As of April 30, 2011
 $1,852  $1,756  $2,171  $5,779 
As of October 31, 2010
 $1,564  $1,635  $2,245  $5,444